Talphera Inc
TLPH0.405USD
+0.001+0.17%
交易中 （美東）報價延遲15分鐘
6.92M總市值
虧損本益比TTM
關於 Talphera Inc 公司
Talphera, Inc.（前身爲 AcelRx Pharmaceuticals, Inc.）是一家專業製藥公司。該公司專注於開發和商業化用於醫療監督環境的療法。該公司的萘莫司他候選產品包括 Niyad 和 LTX-608。Niyad 專注於開發用於注射到體外循環中的局部抗凝劑，例如醫院急性腎損傷 (AKI) 患者在持續性腎臟替代治療 (CRRT) 期間的透析循環，以及透析中心接受間歇性血液透析 (IHD) 的慢性腎病患者。LTX-608 是用於直接靜脈 (IV) 輸注的萘莫司他製劑，應被研究和開發爲治療 COVID、急性呼吸窘迫綜合徵 (ARDS) 瀰漫性血管內凝血 (DIC) 和急性胰腺炎的潛在抗病毒藥物。該公司還致力於開發兩種預充式注射器，即 Fedsyra 和 PFS-02。
公司簡介
公司代碼TLPH
公司名稱Talphera Inc
上市日期Feb 11, 2011
CEOMr. Vincent J. (Vince) Angotti
員工數量13
證券類型Ordinary Share
年結日Feb 11
公司地址1850 Gateway Drive
城市SAN MATEO
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編94404
電話16502163500
網址https://talphera.com/
公司代碼TLPH
上市日期Feb 11, 2011
CEOMr. Vincent J. (Vince) Angotti
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Badri N. Dasu
Mr. Badri N. Dasu
Chief Engineering Officer
Chief Engineering Officer
66.46K
+221.21%
Dr. Shakil Aslam
Dr. Shakil Aslam
Chief Development Officer, Chief Medical Officer
Chief Development Officer, Chief Medical Officer
42.48K
-9.61%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
13.34K
+4.55%
Mr. Mark Allen Wan
Mr. Mark Allen Wan
Independent Director
Independent Director
4.59K
+14.49%
Mr. Abhinav Jain
Mr. Abhinav Jain
Independent Director
Independent Director
2.46K
-19.08%
Mr. Raffi M. Asadorian
Mr. Raffi M. Asadorian
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Jill M. Broadfoot
Ms. Jill M. Broadfoot
Independent Director
Independent Director
--
--
Mr. Vincent J. (Vince) Angotti
Mr. Vincent J. (Vince) Angotti
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Marina S. Bozilenko
Ms. Marina S. Bozilenko
Independent Director
Independent Director
--
--
Dr. Stephen J. Hoffman, M.D., Ph.D.
Dr. Stephen J. Hoffman, M.D., Ph.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Badri N. Dasu
Mr. Badri N. Dasu
Chief Engineering Officer
Chief Engineering Officer
66.46K
+221.21%
Dr. Shakil Aslam
Dr. Shakil Aslam
Chief Development Officer, Chief Medical Officer
Chief Development Officer, Chief Medical Officer
42.48K
-9.61%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
13.34K
+4.55%
Mr. Mark Allen Wan
Mr. Mark Allen Wan
Independent Director
Independent Director
4.59K
+14.49%
Mr. Abhinav Jain
Mr. Abhinav Jain
Independent Director
Independent Director
2.46K
-19.08%
Mr. Raffi M. Asadorian
Mr. Raffi M. Asadorian
Chief Financial Officer
Chief Financial Officer
--
--
收入明細
單位: USD更新時間: 3月5日 週三
單位: USD更新時間: 3月5日 週三
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
業務USD
名稱
營收
佔比
DSUVIA
1.59M
89.67%
DZUVEO
183.00K
10.33%
Zalviso
0.00
0.00%
Non-cash royalty revenue related to Royalty Monetization
0.00
0.00%
Other revenue
0.00
0.00%
Other
0.00
0.00%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
DSUVIA
1.59M
89.67%
DZUVEO
183.00K
10.33%
Zalviso
0.00
0.00%
Non-cash royalty revenue related to Royalty Monetization
0.00
0.00%
Other revenue
0.00
0.00%
Other
0.00
0.00%
股東統計
更新時間: 8月1日 週五
更新時間: 8月1日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Rosalind Advisors, Inc.
9.77%
Nantahala Capital Management, LLC
9.72%
Armistice Capital LLC
4.34%
Bleichroeder LP
2.08%
Angotti Vincent J
1.79%
Other
72.29%
持股股東
持股股東
佔比
Rosalind Advisors, Inc.
9.77%
Nantahala Capital Management, LLC
9.72%
Armistice Capital LLC
4.34%
Bleichroeder LP
2.08%
Angotti Vincent J
1.79%
Other
72.29%
股東類型
持股股東
佔比
Hedge Fund
25.46%
Investment Advisor
4.28%
Individual Investor
2.62%
Investment Advisor/Hedge Fund
1.06%
Research Firm
0.45%
Venture Capital
0.07%
Other
66.06%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
79
6.96M
33.93%
-504.17K
2025Q1
82
6.66M
34.60%
-832.94K
2024Q4
84
5.24M
30.79%
-2.31M
2024Q3
100
5.33M
31.39%
-2.35M
2024Q2
109
5.51M
32.40%
-2.29M
2024Q1
113
5.56M
32.76%
-881.00K
2023Q4
117
5.91M
35.12%
-445.19K
2023Q3
127
7.03M
43.10%
+3.84M
2023Q2
136
1.17M
10.69%
-920.00K
2023Q1
169
1.22M
11.24%
-974.29K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Rosalind Advisors, Inc.
2.00M
9.77%
+1.39M
+226.41%
Mar 31, 2025
Nantahala Capital Management, LLC
1.99M
9.72%
--
--
Apr 25, 2025
Armistice Capital LLC
890.35K
4.34%
-661.26K
-42.62%
Dec 31, 2023
Bleichroeder LP
426.62K
2.08%
+426.62K
--
Mar 31, 2025
Angotti Vincent J
367.85K
1.79%
+265.56K
+259.62%
Apr 25, 2025
Rock Springs Capital Management LP
316.46K
1.54%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
237.53K
1.16%
-3.44K
-1.43%
Mar 31, 2025
Geode Capital Management, L.L.C.
165.61K
0.81%
+2.40K
+1.47%
Mar 31, 2025
Values First Advisors, Inc.
97.32K
0.47%
+771.00
+0.80%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
91.55K
0.45%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
公告日期
類型
比率
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
